type and timing of local and systemic treatments, both overall and progression-free survival were significantly improved on the arm with concurrent chemoradiation with cisplatin. Also, occurrence of distant metastases was demonstrated to be clearly reduced (Morris et al. 1999; Rose et al. 1999; Whitney et al. 1999; Green et al. 2001) .
A variety of agents have been utilized in attemps to improve the local efficacy of radio therapy, but the optimal combination of chemotherapy concurrent with radiotherapy has not yet been determined. The most widely studied combination chemotherapy regimen without radiotherapy for cervical cancer has been ifosfamide and cisplatin (IP) (Stehman et al. 1989; Kuhnle et al. 1990; Filtenborg et al. 1993; Cervelline et al. 1995) . Several phase II trial suggest that the addition of bleomycin to IP (BIP) might improve outcome in women with advanced, recurrent, or progressive squamous cell carcinoma of the cervix (Buxton et al. 1989; Ramm et al. 1992; Tay et al. 1992; Murad et al. 1994) , while a recent report did not show improvement of any outcomes by the addition of bleomycin to IP (Bloss et al. 2002) . BIP stands for bleomycin, ifosfamide and cisplatin. Herod et al. (2000) reported results of a phase III trial comparing neo-adjuvant BIP chemotherapy followed by radiotherapy with the conventional radiotherapy, which failed to show survival benefits of neo-adjuvant BIP. However, there have been no reports that evaluate concurrent use of radiation with BIP. The objective of this study was to evaluate the toxicity and response of the combination of BIP concurrent with radiation in patients with high risk carcinoma of the uterine cervix.
PATIENTS AND METHODS
This study was conducted as retrospective analysis. The eligibility criteria included patients who underwent radical hysterectomy (Type III hysterectomy) as a primary treatment and revealed lymph node metastases or deep myometrial invasion (stage IB and IIA) or patients who were previously untreated (stage IIB-IV). All of the Uterine cervical carcinoma is the second leading cause of death from gynecological malignancies in the great majority of developed countries, and is the main cause of cancer mortality in less developed countries (Pisani et al. 1999 ). In Japan, the incidence of cervical carcinoma has been reported as more than 6,500 cases annually (Paez et al. 1996 ; Japan Society of Obstetrics and Gynecology 2002).
As primary treatment for locally advanced invasive carcinoma of the cervix, radiotherapy alone fails in a substantial number of patients so treated (Perez et al. 1983; Stehman et al. 1991) . Such treatment failure may be due to unrecognized metastatic disease at the time of original diagnosis. Cisplatin is the most effective cytotoxic agent against cervical cancer, and has been shown in cell lines to enhance the effect of radiation (Gibbons and Keys 2000) . Mechanisms that underlie the interaction between drugs and radiation may include inhibition of potentially lethal or sublethal damage repair and an increase in the radiosensitivity of hypoxic cells (Wallner and Li 1987) . Theoretically, the concomitant administration of chemotherapy with radiotherapy could increase local control and survival.
Recently, a number of clinical trials have shown that concurrent chemoradiation was able to significantly improve survival compared to conventional exclusive radiotherapy for adjuvant and primary therapy in cervical carcinoma (Keys et al. 1999; Morris et al. 1999; Rose et al. 1999; Whitney et al. 1999; Perters et al. 2000; Bloss et al. 2002) . From 1998 to 2000, nine randomized controlled trials of concurrent chemoradiation including cisplatin for cervical cancer have been published (Thomas et al. 1998; Keys et al. 1999; Morris et al. 1999; Rose et al. 1999; Whitney et al. 1999; Wong et al. 1999; Perters et al. 2000; Roberts et al. 2000; Pearcey et al. 2002) , six of which showed benefit for concurrent chemoradiation (Keys et al. 1999; Morris et al. 1999; Rose et al. 1999; Whitney et al. 1999; Wong et al. 1999; Perters et al. 2000) . Although there are broad differences in trial design, especially with respect to patients had biopsy-proven squamous cell carcinoma (SCC) of the uterine cervix. Patients were required to have adequate pulmonary, renal, hematologic, and hepatic function. Patients with previous or concomitant other cancers were not eligible in this study. Written informed consent was obtained from all patients before treatment. The research protocol was approved by the ethics committee of Tohoku University Graduate School of Medicine, Sendai, Japan.
In general, patients with stage IB-IIA, who underwent radical hysterectomy received a total of 50 Gy of external pelvic radiation within 6 weeks of surgery, and patients with stage IIB-IV received a total of 50 Gy of external pelvic, and 18-30 Gy of intracavitary radiation. The volume irradiated included the totality of the obvious disease and included the uterus, cervix, parametrial, paracervical , and uterosacral regions as well as the external iliac and obturator lymph nodes. A paraaortic boost was added when paraaortic lymph node metastasis was recognized by computed tomography. Radiotherapy was withheld for grade 3 or 4 hematologic toxicity.
Concomitant chemotherapy was administered on the first day of radiotherapy, 3 courses every 3 weeks as follows: intravenous infusion of ifosfamide 1.5 g/ body, days 1-3; intravenous infusion of bleomycin 10 mg/ body, days 1-3; intravenous infusion of cisplatin 50 mg/ m 2 , day 3. The dosage of anticancer drug in this study was determined according to the dosage of BIP chemotherapy without radiation that had been administrated in our institution. Chemotherapy was withheld until the white blood cell count was greater than 3,000/ μ l and the platelet count was greater than 100,000/ μ l.
Data were collected regarding age, stage, performance status, preoperative and postoperative serum SCC antigen level, courses of chemotherapy, response to the treatment, and adverse effect of treatment. Stage was defined according to the criteria of the International Federation of Gynecology and Obstetrics (FIGO). Performance status was defined according to WHO criteria.
Response to treatment was evaluated according to the Response Evaluation Criteria in Solid Tumours (RECIST) (Therasse et al. 2000) . Toxicity of treatment was graded according to the common toxicity criteria of national cancer institution (NCI-CTC).
RESULTS
From January 2000 to December 2003, 30 patients met study eligibility criteria. Patient characteristics are shown in Table 1 . All but three patients completed three courses of planned chemotherapy. Of three patients who could not com- plete, one had acute renal failure after first course, and the others suffered from severe hematological toxicity after second courses. Seven (23.3%) patients required treatment interruption due to acute hematological toxicity. Four (13.3%) patients required a reduction (up to 30%) in chemotherapy dosage due to the hematological toxicity. Median Serum SCC levels were remarkably decreased after treatment as shown in Table 1 . Adverse effects by treatment were described in Table 2 . The most common toxicity was nausea and vomiting (90%), whereas the most severe was neutrocytopenia. The incidence of grade 3 and 4 toxicity was as follows : anemia, 46.7%; neutrocytopenia, 73.3%; thrombocytopenia, 16.7%; diarrhea, 23.3%; nausea and vomiting, 23.3%; hematuria, 3.3%; and dyspnea, 3.3% . No treatment-related death occurred during therapy.
Twenty-two patients were evaluable for objective response as shown in Table 3 . Eight patients could not be evaluated (NE) because there was no residual tumor after surgery. Four patients who underwent radical hysterectomy were evaluable because of residual lymph node. Complete disappearance of all clinical evidence of disease was achieved in 16 (72.7%) of patients, with a complete response (CR) and partial response (PR) rate of 90.9%. Among patients with clinical stage IIIB-IVB disease, the response rate (CR + PR) was 80% (4/5).
DISCUSSION
In February 1999, the US National Cancer Institute (NCI) issued an alert that chemoradiation should be considered for all patients with cervical cancer. However, the optimal combination of chemotherapy concurrent with radiotherapy has not yet been defined. To our knowledge, this is the first study to evaluate the toxicity and response of BIP chemoradiation in patients with carcinoma of the uterine cervix. Complete response rates of previous chemoradiation studies, together with our study, are summarized in Table  4 . Ogawa et al. (2003) recently reported the results of radiotherapy with high dose rate remote after loading system (HDR-RALS) for uterine cervical cancer in our institution, in which complete response was observed in 75.6%. With regard to response rate, our result was comparable and even superior with those of the previous study.
When radiotherapy and chemotherapy are given together, the evaluation of toxicities becomes important. Chemotherapy toxicity might be harmful if radiotherapy is long lasting, since the efficacy of local control has been shown to fall by up to 1% per day if treatment continues beyond 7 weeks (Perez et al. 1995) . In metaanalysis, acute toxicity, predominantly leucopenia and gastrointestinal symptoms, was increased in the combined chemoradiation groups compared with radiation alone in all trials (Green et al. 2001) . The frequency of acute severe toxicity (grade 3 and 4) was 5.6% (64/1141) for hemoglobin, 16.3% (216/1328) for white blood cell count, 1.4% (18/1223) for platelets, and 28.7% for hematological not otherwise specified (Green et al. 2001 ). In our study, the frequency of grade 3 and 4 was higher than the previous chemoradiation study. Bleomycin is feared for its induction of sometimes fatal pulmonary toxicity, also known as bleomycin-induced pneumonitis, but the incidence of dyspnea was not increased in the present study. The hematological toxicity of BIP chemoradiation seems to be severe in the present dose and manner.
The present study is the first to evaluate the response and toxicity of BIP chemoradiation. The response rate of BIP chemoradiation is comparable or even superior to previously reported chemoradiation regimens, although its toxicity seemed to be severe. Moreover, the study has not been carried out as a prospective study, and the dosage of anticancer drug has not been determined by phase I study. Further prospective and dose-response studies are needed to develop the optimal combination of BIP chemoradiation. 
